DE2538095A1 - NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE - Google Patents
NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USEInfo
- Publication number
- DE2538095A1 DE2538095A1 DE19752538095 DE2538095A DE2538095A1 DE 2538095 A1 DE2538095 A1 DE 2538095A1 DE 19752538095 DE19752538095 DE 19752538095 DE 2538095 A DE2538095 A DE 2538095A DE 2538095 A1 DE2538095 A1 DE 2538095A1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- formula
- carbon atoms
- above meaning
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000002894 organic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 5
- HONLKDDLTAZVQV-UHFFFAOYSA-N eburnamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)N5C2=C1 HONLKDDLTAZVQV-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229950002496 vincanol Drugs 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- HONLKDDLTAZVQV-UHOSZYNNSA-N vincanol Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@H](O)N5C2=C1 HONLKDDLTAZVQV-UHOSZYNNSA-N 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- BVWWUWXMEWKEMC-UHFFFAOYSA-N O-methyleburnamine Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(OC)N5C2=C1 BVWWUWXMEWKEMC-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910000039 hydrogen halide Inorganic materials 0.000 description 2
- 239000012433 hydrogen halide Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BVWWUWXMEWKEMC-RLLQIKCJSA-N o-methylepivincanol Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@@H](OC)N5C2=C1 BVWWUWXMEWKEMC-RLLQIKCJSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052783 alkali metal Chemical group 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003970 cerebral vascular damage Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002582 psychostimulating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
Description
SAKDOZ-PATENT-GMBH Case 100-4220'SAKDOZ-PATENT-GMBH Case 100-4220 '
7850 L ö r r a c h7850 L ö r r a c h
Neue organische Verbindungen., ihre Herstellung und Verwendung New organic compounds, their production and uses
Gegenstand der Erfindung sind Verbindungen der Formel I, worinThe invention relates to compounds of the formula I, in which
X Wasserstoff oder" .ein in 10- .oder 11-Stellung ständiges Halogen mit einem Atomgewicht unter 80 "bedeutet undX hydrogen or ".ein in 10-. Or 11-position permanent halogen with an atomic weight below 80 "means and
R für einen Rest der Reihe OR1, SR3, KR3R4 steht, wobeiR stands for a radical from the series OR 1 , SR 3 , KR 3 R 4 , where
R, und R2 Alkyl mit 1 bis 4 Kohlenstoffatomen, eineR, and R 2 are alkyl of 1 to 4 carbon atoms, one
Hydroxyalkyl- oder Aminoalkylgruppe mit 2 bis 4 Kohlenstoffatomen, Phenyl oder Phenylalkyl mit 7 bis 10 Kohlenstoffatomen bedeuten undHydroxyalkyl or aminoalkyl group with 2 to 4 carbon atoms, phenyl or Denote phenylalkyl with 7 to 10 carbon atoms and
R3 und R4 für Viasserstoff, Alkyl mit 1 bis 4 Kohlen-R 3 and R 4 for hydrogen, alkyl with 1 to 4 carbons
609813/1020609813/1020
- 2 - 100-4220- 2 - 100-4220
Stoffatomen, Phenyl oder Phenylalkyl mit 7 bis 10 Kohlenstoffatomen stehen,Substance atoms, phenyl or phenylalkyl with 7 to 10 carbon atoms,
in Form der Basen oder von Säureadditionssalzen.in the form of bases or of acid addition salts.
X bedeutet insbesondere Wasserstoff, Fluor oder Brom. steht X für Fluor, dann ist es vorzugsweise 10-ständig; steht X für Brom, dann ist es vorzugsweise 11-ständig. R bedeutet vorzugsweise SR3.X denotes in particular hydrogen, fluorine or bromine. if X is fluorine, then it is preferably in the 10 position; X stands for bromine, then it is preferably 11-position. R preferably denotes SR 3 .
Stehen R1 oder R2 für Alkyl mit 1 bis 4 Kohlenstoffatomen, co bedeuten sie insbesondere Methyl oder Aethyl, vorzugsweise Methyl.R 1 or R 2 represents alkyl having 1 to 4 carbon atoms, co they mean in particular methyl or ethyl, preferably methyl.
Stehen R1 oder R3 für Hydroxyalkyl mit 2 bis 4 Kohlenstoffatomen, so bedeuten sie vorzugsweise 2-Hydroxyäthyl. Die Hydroxygruppe steht nicht in Gestellung zum Heteroatom, woran R1 oder R3 gebunden ist.If R 1 or R 3 are hydroxyalkyl with 2 to 4 carbon atoms, they are preferably 2-hydroxyethyl. The hydroxyl group is not in the position of the heteroatom to which R 1 or R 3 is bonded.
Stehen R. oder R^ für Aminoalkyl mit 2 bis 4 Kohlenstoffatomen, so bedeuten sie vorzugsweise 2-Aminoätliyl. Die Aminogruppe steht nicht in α-Stellung zum Heteroatom, woran R. oder R gebunden ist.R. or R ^ stand for aminoalkyl with 2 to 4 carbon atoms, they are preferably 2-aminoethyl. The amino group is not in the α position to the heteroatom to which R. or R is bonded.
Stehen R1 odor R2 für Phenylalkyl mit 7 bis 10 Kohlenstoffatomen, so bedeuten sie vorzugsweise Renzyl oder 2-PhenylSthyl.If R 1 or R 2 are phenylalkyl with 7 to 10 carbon atoms, they are preferably renzyl or 2-phenyl-thyl.
R. steht Insbesondere für Methyl. R3 steht insbe sondere für Methyl oder 2-Hydroxyitthyl.R. particularly stands for methyl. R 3 stands in particular for methyl or 2-hydroxyethyl.
Stehen R3 oder R4 für Alkyl mit 1 bis 4 Kohlenstoffatomen, so bedeuten sie insbesondere Methyl odor ΛοΙ-hyl, Vorzügen·/«!ine Methyl.If R 3 or R 4 are alkyl having 1 to 4 carbon atoms, they are in particular methyl or ΛοΙ-hyl, preference / ine methyl.
6 09813/10206 09813/1020
- 3 - 100-4220- 3 - 100-4220
Stehen R3 oder R4 für Phenylalkyl mit 7 bis 10 Kohlenstoffatomen, so bedeuten sie vorzugsweise Benzyl oder 2-Phenyläthyl.If R 3 or R 4 are phenylalkyl with 7 to 10 carbon atoms, they are preferably benzyl or 2-phenylethyl.
Erfindungsgemäss gelangt man zu den Verbindungen der Formel I, indem manThe compounds are obtained according to the invention of formula I by
a) zur Herstellung von Verbindungen der Formel Ia, worin R1 für einen Rest OR oder SR3 steht in denen R^ und R3 obige Bedeutung besitzen, und X obige Bedeutung besitzta) for the preparation of compounds of the formula Ia in which R 1 is a radical OR or SR 3 in which R ^ and R 3 have the above meaning and X has the above meaning
Verbindungen der Formel II, worin R1obige Bedeutung besitzt, an Verbindungen der Formel III, worin X obige Bedeutung besitzt, addiert oderCompounds of the formula II in which R 1 has the above meaning, added or added to compounds of the formula III in which X has the above meaning
b) in Verbindungen der Formel IV, worin X obige Bedeutung besitzt und Z einen gegen R austauschbaren Rest bedeutet, den Rest Z durch den Rest R substituiert.b) in compounds of the formula IV in which X has the above meaning and Z has one which can be exchanged for R Radical means the radical Z is substituted by the radical R.
Die Verfahren a) und b) können analog zu bekannten Methoden durchgeführt werden.Processes a) and b) can be carried out analogously to known methods.
Verfahren a) ist eine Additionsreaktion. Sie wird unter sauren Bedingungen durchgeführt, zweckmässig unter Ausschluss von Wasser. Man verwendet z.B. 1,0 bis 2,0 Mol Säure, beispielsweise Schwefeloder Methansulfonsäure, pro Mol Verbindung III.Method a) is an addition reaction. It is carried out under acidic conditions, expediently excluding water. For example, 1.0 to 2.0 moles of acid are used, for example sulfur or Methanesulfonic acid, per mole of compound III.
Man kann in einem unter den Reaktionsbedingungen inerten Lösungsmittel wie Chloroform oder in einem Ueberschuss Verbindung der Formel II arbeiten.You can in an inert solvent under the reaction conditions such as chloroform or in a Work excess compound of formula II.
609813/1020609813/1020
- 4 - 100-4220- 4 - 100-4220
Die Reaktionstemperatur kann variieren, beispielsweise von Raumtemperatur bis 80°; im allgemeinen wird die Reaktion zweckmässig bei erhöhter Temperatur, z.B. zwischen 40 bis 80°, durchgeführt.The reaction temperature can vary, for example from room temperature to 80 ° ; In general, the reaction is expediently carried out at an elevated temperature, for example between 40 ° to 80 °.
Verfahren b) ist eine nukleophile Substitutionsreaktion, die z.B. durch Umsetzung einer Verbindung der Formel IV mit einer Verbindung der Formel V worin M Wasserstoff oder ein Alkalimetall bedeutet und R obige Bedeutung besitzt, ausgeführt werden kann.Method b) is a nucleophilic substitution reaction, for example by reacting a compound of the formula IV with a compound of the formula V in which M is hydrogen or an alkali metal means and R has the above meaning, can be carried out.
Z bedeutet in den Verbindungen der Forme]. IV z.B. Halogen, beispielsweise Brom oder Chlor. M bedeutet in den Verbindungen der Formel V z.B. Natrium , Lithium, Kalium oder Wasserstoff.Z in the compounds of the form means]. IV e.g. halogen, e.g. bromine or chlorine. In the compounds of the formula V, M denotes, for example, sodium, lithium, potassium or hydrogen.
Die Verbindungen der Formel IV, in denen Z für Halogen steht, sind Halogenwasserstoffadditionsprodukte von Verbindungen der Formel III. Sie sind instabil. Bei ihrer Umsetzung mit einer Verbindung der Formel V wird zweckmMsslg unter -20° gearbeitet.The compounds of the formula IV in which Z represents halogen are hydrogen halide addition products of compounds of the formula III. You are unstable. When implementing them with a connection the formula V is expediently worked below -20 °.
Als Lösungsmittel wählt man z.B. einen Ueberschuss der eingesetzten Verbindung der Formel V, soweit diese bei dieser Temperatur flüssig ist, oder man arbeitet mit einem bei der Reaktionstemperatur noch flüssigen, unter den Reaktionsbedingungen inerten Lösungs- bzw. Suspensionsmittel wie Hexan. The solvent chosen is, for example, an excess of the compound of the formula V used, provided it is liquid at this temperature, or a solvent or suspending agent such as hexane which is still liquid at the reaction temperature and which is inert under the reaction conditions is used.
609813/1020609813/1020
- 5 - 100-4220- 5 - 100-4220
Bei den Umsetzungen gemäss Verfahren a) oder b) entsteht jeweils ein Gemisch von Verbindungen der Formel I, in denen R in trans-Stellung zum Wasserstoffatom in Stellung C3 steht (Epivincanolderivate), und Verbindungen der Formel I, in denen R in cis-Stellung zum Wasserstoffatom in Stellung C3 steht (Vincanolderivate). Ihre Auftrennung kann analog zu bekannten Methoden, beispielsweise durch fraktionierte Kristallisation oder Chromatographie erfolgen.The reactions according to process a) or b) result in each case a mixture of compounds of the formula I in which R is in the trans position to the hydrogen atom in the C 3 position (epivincanol derivatives), and compounds of the formula I in which R in cis- Position to the hydrogen atom is in position C 3 (vincanol derivatives). Their separation can be carried out analogously to known methods, for example by fractional crystallization or chromatography.
Die nach dem erfindungsgemässen Verfahren erhältlichen Verbindungen der Formel I können in freier Form, als Base, oder in Form ihrer Additionssalze mit Säuren vorliegen, Aus den freien Basen lassen sich in bekannter Weise Säureadditionssalze, z.B. das Eydrogenfumarat, herstellen und umgekehrt.The compounds of the formula I obtainable by the process according to the invention can be present in free form, as a base, or in the form of their addition salts with acids. Acid addition salts, for example hydrogen fumarate, can be prepared from the free bases in a known manner, and vice versa.
Die Ausgangsprodukte sind bekannt oder nach an sich bekannten Methoden herstellbar.The starting products are known or can be prepared by methods known per se.
Die Verbindungen der Formel I in freier Form oder in Form von physiologisch verträglichen Additicnssalzen ir.it Säuren (erfindungsgemässe Verbindungen) zeichnen sich durch interessante pharmakcdynamische Eigenschaften aus. Sie können als HeiImIt-'tel verwendet werden*The compounds of the formula I in free form or in the form of physiologically compatible additive salts ir. with acids (compounds according to the invention) are characterized by interesting pharmaccdynamic Properties. As HeiImIt-'tel be used*
So sind sie nützlich, da sie vigilanzerhöhende und psychostimulierenae Eigenschaften besitzen.They are useful because they have vigilance-increasing and psychostimulating properties.
609813/1020609813/1020
- 6 - 100-4220- 6 - 100-4220
Aufgrund dieser Wirkung sind die erfindungsgemässigen Verbindungen z.B. indiziert bei zerebralen Gefässchädigungen, bei der Zerebralskelerose, bei Zerebralinsuffizienz oder bei Bewusstseins-Verlusten aufgrund von Schädeltraumata.Die Vincanolderivate sind bevorzugt.Because of this effect, the inventive Connections e.g. indicated in cerebral vascular damage, in cerebral kerosis, in the case of cerebral insufficiency or loss of consciousness due to head trauma are preferred.
Die Erfindung betrifft auch Heilmittel, die eine Verbindung der Formel I in freier Form oder in Form ihrer physiologisch verträglichen Additions-Balze mit Säuren enthalten. Diese Heilmittel, beispielsweise eine Lösung oder eine Tablette, können nach bekannten Methoden, unter Verwendung der üblichen Hilfs- und Trägerstoffe, hergestellt werden.The invention also relates to medicaments which contain a compound of the formula I in free form or in In the form of their physiologically compatible addition-Balze with acids. These remedies for example a solution or a tablet can be made using known methods the usual auxiliary and carrier materials will.
Die nachfolgenden Beispiele erläutern die Erfindung,The following examples explain the invention,
609813/1020609813/1020
253809S253809S
100-4220100-4220
HR1 HR 1
IIII
MRMR
609813/ 1020 Ia609813/1020 Ia
III IVIII IV
- 8 - 100-4220- 8 - 100-4220
Beispiel 1: 14-ϋεοχγ-14-_(2-hYdroxYäthYl thio )_- yincanol (Verfahren a) Example 1 : 14-ϋεοχγ-14 -_ (2-hydroxYäthYl thio) _- yincanol (method a)
13,92 g (50 mmol) (3S,16S)—Eburnamenin und 4,69 g (60 mmol) Mercaptoäthanol wurden in 60 ml 1 M Methansulfonsäurelösung in Chloroform gelöst und 2 Stunden bei 20° stehengelassen. Nach Verteilen zwischen 50 ml 2N wässrigem Ammoniak und Methylen chlorid ,Trocknen und Eindampfen erhielt man einen harzigen Rückstand. Kristallisation aus 2-Propanol bei 0° lieferte die TiteJ.verbindung vom Smp. 175°.13.92 g (50 mmol) (3S, 16S) -Eburnamenin and 4.69 g (60 mmol) of mercaptoethanol were dissolved in 60 ml of 1 M methanesulfonic acid solution in chloroform and Left to stand for 2 hours at 20 °. After partitioning between 50 ml of 2N aqueous ammonia and methylene chloride, drying and evaporation gave a resinous residue. Crystallization from 2-propanol at 0 ° the title compound of m.p. 175 °.
27,84 g (100 mmol) (3S,16S)-Eburnamenin wurden in 100 ml 1 M absolut-methanolischer Schwefelsäure gelöst und 30 Minuten unter Stickstoff gesiedet. Nach Verteilung zwischen 200 ml 2K Ammoniak und Methylenchlorid, Trocknen und Eindampfen erhielt man amorphes Material, bestehend aus einem Gemisch der beiden epimeren Basen. Fraktionierte Kristallisation der Hydrogenfumarate aus 2-Propanol bei 0° lieferte zuerst Kristalle von O-Methylvincanolhydrogenfumarat, Smp. 161° (Zers.), dann Kristalle von O-Methylepivincanolhydrogenfumarat, Smp. 110° (Zers.).27.84 g (100 mmol) (3S, 16S) -Eburnamenin were in Dissolve 100 ml of 1 M absolute methanolic sulfuric acid and boil for 30 minutes under nitrogen. After distribution between 200 ml of 2K ammonia and methylene chloride, drying and evaporation obtained amorphous material consisting of a mixture of the two epimeric bases. Fractional crystallization the hydrogen fumarate from 2-propanol at 0 ° first gave crystals of O-methylvincanol hydrogen fumarate, M.p. 161 ° (decomp.), Then crystals of O-methylepivincanol hydrogen fumarate, m.p. 110 ° (decomp.).
Freisetzung der Basen erfolgte jeweils durch Verteilen zwischen 2N wässrigem Ammoniak und Me-The bases were released in each case by distributing between 2N aqueous ammonia and
6 0 9 8 13/10206 0 9 8 13/1020
- 9 - 100-4220- 9 - 100-4220
thylenchlorid. Kristallisation der erhaltenen öligen Rückstände aus 2-Propanol ergabethylene chloride. Crystallization of the obtained oily residues from 2-propanol resulted
O-Methylvincanol vom Smp. 106° bzw. O-Methylepivincanol vom Smp. 163°. O-methylvincanol with a melting point of 106 ° or O-methylepivincanol with a melting point of 163 °.
Beispiel 3; 14ΐ2εοχγ-14-methylthio-vincanol (Verfahren b) Example 3 ; 14ΐ2εοχγ-14-methylthio-vincanol (method b)
a) Darstellung des Halogenwasserstoffadditionsproa) Representation of the hydrogen halide addition pro
Zu 27,84 g (3S,16S)-Eburnamenin wird unter Rühren bei -78° absolutes Bromwasserstoffgas geleitet und kondensiert, bis sich bei einem Volumen von 100 ml eine klare gelbe Lösung bildet.For 27.84 g of (3S, 16S) -Eburnamenin is added under Stirring passed at -78 ° absolute hydrogen bromide gas and condensed until at a Volume of 100 ml forms a clear yellow solution.
Stets noch im Trockeneisbad wird dann bei einem Vakuum von 200 Torr unter Rühren bis zum erstarrenden Brei eingeengt und der Rückstand anschliessend ohne Rühren 16 Stunden bei 20 Torr und -78° getrocknet. Nach Entlasten des Vakuums mit Stickstoff wird der spröde Rückstand bei -78° pulverisiert.Always still in the dry ice bath, then at a vacuum of 200 Torr while stirring until it solidifies The pulp is concentrated and the residue is then left without stirring for 16 hours at 20 torr and -78 ° dried. After releasing the vacuum with nitrogen, the brittle residue is at -78 ° powdered.
Zum pulverisierten Rückstand gibt man bei -78° unter Rühren 100 ml Methanthiol hinzu, lässt100 ml of methanethiol are added to the pulverized residue at -78 ° with stirring
609813/1020609813/1020
100-4220100-4220
unter Rühren während einer Stunde auf 0° aufwärmen und eine Stunde bei 0° weiterrühren. Hierauf verteilt man das Reaktionsgemisch zwischen 500 ml 2N-Ammoniak und 200 ml Methylenchlorid, dampft die Methylenchloridlösung ein und kristallisiert die Titelverbindung aus Methanol. Smp. 199°.warm up to 0 ° for one hour while stirring and continue stirring at 0 ° for one hour. The reaction mixture is then distributed between 500 ml of 2N ammonia and 200 ml of methylene chloride, the methylene chloride solution is evaporated and the title compound is crystallized from methanol. M.p. 199 °.
Analog zu Beispiel 1 erhält man unter Verwendung der entsprechenden Verbindungen der Formeln.II und III folgende Verbindungen der Formal IaAnalogously to Example 1, using the appropriate compounds of the formulas. II and III the following compounds of formula Ia
5
6
74th
5
6th
7th
H
H
FH
H
H
F.
des p-Toluolsulfonats
. 167°
199°
155°95 °
of p-toluenesulfonate
. 167 °
199 °
155 °
—^S(CH2J3CH3
---.SCH3
·»·· .»SCH—SCH (CH 3 ) 2
- ^ S (CH 2 J 3 CH 3
---. SCH 3
·"·· ."NS-
Verfährt man analog zu Beispiel 3, erhält man unter Verwendung der entsprechenden Ausgangsverbindungen der Formel IV, worin Z Br bedeutet, folgende Verbindungen der Formel IIf one proceeds analogously to Example 3, one obtains under Use of the corresponding starting compounds of the formula IV in which Z is Br, the following compounds of formula I.
609 813/1020609 813/1020
- li -- li -
100-4220100-4220
•ij• ij
I
I f
I.
I.
ιι
rr
I
I I.
I.
I.
t
I t
t
I.
tt
II.
tt
Q)Q)
609813/1020609813/1020
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH1215374A CH602734A5 (en) | 1974-09-06 | 1974-09-06 | Vincanol derivs |
CH711875A CH609984A5 (en) | 1975-06-03 | 1975-06-03 | Process for the preparation of novel compounds of the vincanol-epivincanol group |
Publications (1)
Publication Number | Publication Date |
---|---|
DE2538095A1 true DE2538095A1 (en) | 1976-03-25 |
Family
ID=25700781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19752538095 Withdrawn DE2538095A1 (en) | 1974-09-06 | 1975-08-27 | NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE |
Country Status (14)
Country | Link |
---|---|
US (1) | US4045443A (en) |
JP (1) | JPS5154600A (en) |
AU (1) | AU8456775A (en) |
DD (1) | DD121943A5 (en) |
DE (1) | DE2538095A1 (en) |
DK (1) | DK388475A (en) |
ES (2) | ES440723A1 (en) |
FI (1) | FI752423A (en) |
FR (1) | FR2342065A1 (en) |
GB (1) | GB1518987A (en) |
IL (1) | IL48054A (en) |
NL (1) | NL7510315A (en) |
NO (1) | NO752972L (en) |
SE (1) | SE7509657L (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190658A (en) | 1977-07-25 | 1980-02-26 | Roussel Uclaf | 14-Imino-(15H)-eburnamine compounds, compositions, methods of use and process of synthesis |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU173511B (en) * | 1976-07-21 | 1979-05-28 | Richter Gedeon Vegyeszet | Process for preparing vincamenine further salts and molecular compounds thereof |
HU180929B (en) * | 1979-08-13 | 1983-05-30 | Richter Gedeon Vegyeszet | Process for producing new bromo-vincamone derivatives |
JPS56161388A (en) | 1980-05-16 | 1981-12-11 | Nippon Zoki Pharmaceut Co Ltd | Novel vincamine derivative |
JPS5732281A (en) * | 1980-08-06 | 1982-02-20 | Sumitomo Chem Co Ltd | Nitrogen-containing polycyclic compound and its preparation |
FR2623501B1 (en) * | 1987-11-19 | 1990-03-16 | Roussel Uclaf | NOVEL SUBSTITUTED DERIVATIVES OF 20.21-DINOREBURNAMENINE, THEIR PREPARATION PROCESS AND THE NOVEL INTERMEDIATES THUS OBTAINED, THEIR APPLICATION AS DRUGS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2869034B1 (en) * | 2004-04-14 | 2008-04-04 | Biocortech Soc Par Actions Sim | 14,15-DIHYDRO 20,21-DINOREBURNAMENIN 14-OL DERIVATIVE AND THEIR USE FOR TREATING DEPRESSIONS |
-
1975
- 1975-08-27 DE DE19752538095 patent/DE2538095A1/en not_active Withdrawn
- 1975-08-28 FI FI752423A patent/FI752423A/fi not_active Application Discontinuation
- 1975-08-28 DK DK388475A patent/DK388475A/en unknown
- 1975-08-29 NO NO752972A patent/NO752972L/no unknown
- 1975-08-29 SE SE7509657A patent/SE7509657L/en unknown
- 1975-09-02 NL NL7510315A patent/NL7510315A/en not_active Application Discontinuation
- 1975-09-02 FR FR7526884A patent/FR2342065A1/en active Granted
- 1975-09-02 US US05/609,357 patent/US4045443A/en not_active Expired - Lifetime
- 1975-09-03 GB GB36242/75A patent/GB1518987A/en not_active Expired
- 1975-09-04 IL IL48054A patent/IL48054A/en unknown
- 1975-09-04 DD DD188188A patent/DD121943A5/xx unknown
- 1975-09-04 ES ES440723A patent/ES440723A1/en not_active Expired
- 1975-09-04 AU AU84567/75A patent/AU8456775A/en not_active Expired
- 1975-09-05 JP JP50107161A patent/JPS5154600A/ja active Pending
-
1977
- 1977-03-01 ES ES456416A patent/ES456416A1/en not_active Expired
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4190658A (en) | 1977-07-25 | 1980-02-26 | Roussel Uclaf | 14-Imino-(15H)-eburnamine compounds, compositions, methods of use and process of synthesis |
Also Published As
Publication number | Publication date |
---|---|
ES456416A1 (en) | 1978-06-16 |
JPS5154600A (en) | 1976-05-13 |
ES440723A1 (en) | 1977-07-01 |
DK388475A (en) | 1976-03-07 |
NO752972L (en) | 1976-03-09 |
US4045443A (en) | 1977-08-30 |
FR2342065B1 (en) | 1978-09-08 |
FI752423A (en) | 1976-03-07 |
NL7510315A (en) | 1976-03-09 |
SE7509657L (en) | 1976-03-08 |
IL48054A0 (en) | 1975-11-25 |
FR2342065A1 (en) | 1977-09-23 |
GB1518987A (en) | 1978-07-26 |
AU8456775A (en) | 1977-03-10 |
DD121943A5 (en) | 1976-09-05 |
IL48054A (en) | 1978-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60035109T2 (en) | PROCESS FOR THE PREPARATION OF THIAMETHOXAM | |
DE2147023A1 (en) | PROCESS FOR PRODUCING 1HTETRAZOLE COMPOUNDS | |
DE2538095A1 (en) | NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE | |
DE1670574A1 (en) | Process for the production of new N-aromatically substituted acid amides II | |
DE2066192C1 (en) | New macrocyclic compounds | |
DE2545329A1 (en) | 1-AMIDE-ALKYL-4-SULFONYL-PIPERAZINE DERIVATIVES | |
CH622518A5 (en) | Process for the preparation of novel ergoline compounds | |
DE1468135C3 (en) | ||
DE1795344A1 (en) | 3-amino-isothiazoles | |
DE2166270C3 (en) | Nicotinoylaminoethanesulfonyl-2amino-thiazole | |
DE934890C (en) | Process for the preparation of basic benzhydryl ethers | |
DE1211156B (en) | Process for the production of unsaturated sulfonic acid betaines by reacting a tertiary amine with a sultone | |
DE1670478A1 (en) | Process for the preparation of derivatives of alpha-piperazino-phenylacetonitrile | |
DE2525962A1 (en) | NEW HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | |
DE814595C (en) | Process for the production of sulfonates | |
DE2411848A1 (en) | N-(2-Amino-3,5-dibromobenzyl)-N-methyl-cyclohexylamine prepn - from a 2-amino-3,5-dibromobenzyl alcohol ester and N-methyl-cyclohexylamine, for use as antitussive agent | |
CH615182A5 (en) | ||
DE2735052A1 (en) | SQUARE BRACKET TO N-(2-DIPHENYLMETHOXYAETHYL)-N-(1-METHYL-2-PHENOXYAETHYL)-N-METHYL SQUARE BRACKET TO AMINE, ITS PRODUCTION AND USE IN PHARMACEUTICALS | |
DE3434553C2 (en) | ||
DE1124938B (en) | Process for the preparation of nonionic polyoxycarboxamides | |
DE1024954B (en) | Process for the preparation of N-disubstituted dithiocarbamic acid esters which contain sulfonic acid groups in the alcohol residue | |
DE2518516C3 (en) | 2- (3,45-trimethoxybenzyl) -3,4-dimethylpyridine | |
DE1470243C (en) | Ergoline-I derivatives and a process for their preparation | |
DE1595875C (en) | Phenothiazines and processes for their preparation | |
DE2407004C3 (en) | Fluorinated dienes and methods of making them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |